QTORIN Momentum Continues — Palvella Is a High-Conviction, Event-Driven Long
Palvella's QTORIN rapamycin program delivered clinical proof and the company has fortified its balance sheet with a $230M upsized offering. With a market cap near $1.64B and current price action sitting under recent moving averages, this is an event-driven long for investors who can tolerate biotech binary risk. Entry, stop and target included for …